Portal de Periódicos da CAPES

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

2021; Elsevier BV; Volume: 156; Linguagem: Inglês

10.1016/j.radonc.2021.01.013

1879-0887

Benjamin Lacas, Alexandra Carmel, C. Landais, Stuart J. Wong, Lisa Licitra, Jeffrey Tobias, Barbara Burtness, Maria Grazia Ghi, Ezra E.W. Cohen, Cai Grau, Gregory T. Wolf, Ricardo Hitt, Renzo Corvò, Volker Budach, Shaleen Kumar, Sarbani Ghosh Laskar, Jean‐Jacques Mazeron, Lai‐ping Zhong, W. Dobrowsky, Pirus Ghadjar, C. Fallai, Branko Zakotnik, Atul Sharma, René‐Jean Bensadoun, Maria Grazia Ruo Redda, S. Racadot, George Fountzilas, David M. Brizel, P Rovea, Athanassios Argiris, Zoltán Takácsi Nagy, Ju‐Whei Lee, Catherine Fortpied, Jonathan Harris, Jean Bourhis, Anne Aupérin, Pierre Blanchard, Jean‐Pierre Pignon, David J. Adelstein, M. Alfonsi, Y. Belkacemi, Voichita Bar‐Ad, J. Bernier, Åse Bratland, G. Calais, Brittany Campbell, Jimmy J. Caudell, Sylvie Chabaud, Emmanuel Chamorey, Devendra Chaukar, Kwang Nam Choi, O. Choussy, Laurence Collette, Judith Cruz, Carla Dani, Etienne Dauzier, Arlene A. Forastiere, P. Garaud, V. Grégoire, A. Hackshaw, E. Haddad, Bruce G. Haffty, Aaron R. Hansen, Stefanie Hayoz, Jean-Claude Horiot, Branislav Jeremić, Theodore Karrison, Johannes A. Langendijk, M. Lapeyre, Éric Lartigau, Traci Leong, Quynh‐Thu Le, Patricia Lee, Freddi Lewin, Aihua Lin, Alberto Lopes, Samir Mehta, James Moon, Elizabeth Moyal, Bob-valery Occean, P. Olmi, Roberto Orecchia, Brian O’Sullivan, Jens Overgaard, Claire Petit, Harvey Quon, Giuseppe Sanguineti, Tuvana Satar, John Simes, Christian Simon, Clément Sire, Susanne Staar, C. Stromberger, P. Strojan, Stéphane Temam, David Thomson, A. Timochenko, Valter Torri, Vassilikì Tseroni, Jan B. Vermorken, Everett E. Vokes, John Waldron, Klaus–Dieter Wernecke, Joachim Widder, Björn Zackrisson,

Cleft Lip and Palate Research

The Meta-Analysis of Chemotherapy in squamous cell Head and Neck Cancer (MACH-NC) demonstrated that concomitant chemotherapy (CT) improved overall survival (OS) in patients without distant metastasis. We report the updated results.Published or unpublished randomized trials including patients with non-metastatic carcinoma randomized between 1965 and 2016 and comparing curative loco-regional treatment (LRT) to LRT + CT or adding another timing of CT to LRT + CT (main question), or comparing induction CT + radiotherapy to radiotherapy + concomitant (or alternating) CT (secondary question) were eligible. Individual patient data were collected and combined using a fixed-effect model. OS was the main endpoint.For the main question, 101 trials (18951 patients, median follow-up of 6.5 years) were analyzed. For both questions, there were 16 new (2767 patients) and 11 updated trials. Around 90% of the patients had stage III or IV disease. Interaction between treatment effect on OS and the timing of CT was significant (p < 0.0001), the benefit being limited to concomitant CT (HR: 0.83, 95%CI [0.79; 0.86]; 5(10)-year absolute benefit of 6.5% (3.6%)). Efficacy decreased as patients age increased (p_trend = 0.03). OS was not increased by the addition of induction (HR = 0.96 [0.90; 1.01]) or adjuvant CT (1.02 [0.92; 1.13]). Efficacy of induction CT decreased with poorer performance status (p_trend = 0.03). For the secondary question, eight trials (1214 patients) confirmed the superiority of concomitant CT on OS (HR = 0.84 [0.74; 0.95], p = 0.005).The update of MACH-NC confirms the benefit and superiority of the addition of concomitant CT for non-metastatic head and neck cancer.